News 2016-10-15T14:05:37+00:00
1904, 2017

VLP Therapeutics Receives Notice of Allowance of Key U.S. composition of matter Patent for immune checkpoint PD-1/PD-L1/PD-L2 inserted alphavirus VLP


Patent covers a composition of matter for immune checkpoint PD-1/PD-L1/PD-L2 inserted alphavirus VLP and method of use for cancer therapy Gaithersburg, Md. — April 19, 2017 — VLP Therapeutics, LLC.

103, 2017

VLP Therapeutics Appoints Danai Brooks, Managing Partner of Glen Echo Capital, to Advisory Board


Gaithersburg, Md. — February 27, 2017 — VLP Therapeutics, LLC. (“VLP”), a biotechnology company focusing on the research and development of therapeutic and preventative vaccines and antibody agents, today announced

510, 2016

VLP Therapeutics Receives Grant from Global Health Innovative Technology (GHIT) Fund to Develop New Vaccine for Dengue Fever


Gaithersburg, Md.-- (PR NEWS WIRE) — October 5, 2016 -- VLP Therapeutics, LLC. announced today that it has received a grant for approximately US$960,000 from the Global Health Innovative Technology